KML-010
{{Short description|Chemical compound}}
{{Drugbox
| verifiedrevid = 449582001
| IUPAC_name = 8-[4-(4-fluorophenyl)-4-oxobutyl]-1-methyl-1,3,8-triazaspiro[4.5]decan-4-one
| image = KML-010.svg
| width =
| tradename =
| routes_of_administration =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 217635-62-6
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = V68MR69LDZ
| PubChem = 10404584
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8580022
| C=18 | H=24 | F=1 | N=3 | O=2
| smiles = O=C1NCN(C)C1(CC2)CCN2CCCC(=O)c(cc3)ccc3F
| StdInChI = 1S/C18H24FN3O2/c1-21-13-20-17(24)18(21)8-11-22(12-9-18)10-2-3-16(23)14-4-6-15(19)7-5-14/h4-7H,2-3,8-13H2,1H3,(H,20,24)
| StdInChIKey = GRADLHIYNHRBCW-UHFFFAOYSA-N
}}
KML-010 is a drug derived from spiperone. It functions as a highly selective 5-HT2A receptor antagonist, with negligible affinity for the 5-HT1A or 5-HT2C receptors, and over 400-fold lower affinity for the D2 receptor in comparison to spiperone.{{cite journal |vauthors=Glennon RA, Metwally K, Dukat M, Ismaiel AM, De los Angeles J, Herndon J, Teitler M, Khorana N |title=Ketanserin and spiperone as templates for novel serotonin 5-HT(2A) antagonists |journal=Current Topics in Medicinal Chemistry |volume=2 |issue=6 |pages=539–58 |date=June 2002 |pmid=12052193 |doi= 10.2174/1568026023393787}}